Loading
Life sciences · Journal article
Radiation · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Radioactive iodine (RAI) treatment for thyroid disease may be a treatment option for patients with high-risk differentiated thyroid cancer (DTC) or hyperthyroidism caused by Graves’ disease, toxic multinodular goiter, and toxic adenoma. Despite being a common treatment modality for thyroid disease, the long-term risk of developing cancer after RAI treatment remains unclear. This narrative review aims to discuss current guidelines for the use of RAI in thyroid disease and evaluate current literature regarding the incidence of malignancy after RAI treatment. In those with hyperthyroidism, the evidence for increased risk of cancer after RAI remains mixed, with studies suggesting little to no increased overall cancer risk. However, some studies do demonstrate an increase in organ-specific cancers, including thyroid, breast, kidney, and gastric cancers. In those with DTC, systematic reviews and large meta-analyses demonstrate a small increase in relative risk of hematologic malignancy, corresponding to only a modest increase in absolute incidence. More recent evidence suggests that the risk of malignancy after RAI treatment may have a dose-dependent correlation. Current guidelines for the use of RAI should consider the risk of malignancy associated with this treatment modality.